1. In Vivo
  2. >>Deal-Making

Podcast: Improving Communication – The Relationship Between Biotech And Pharma

 
• By David Wild

Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma. 

In Vivo Podcast
• Source: Shutterstock

"My policy as a doctor was always to be very open and transparent – whether that was about morbidity or mortality I was very open.” 

In this latest instalment of the In Vivo podcast, Treehill Partners founder, CEO and chair Ali Pashazadeh focuses on the need for increased communication between biotech and pharma and their contract organizations (both research and development/manufacturing organizations). Pashazadeh also analyzes how his previous medical experience guides him now, as he attempts to transfer the same ethos held as a doctor and clinician to the world of investment banking.

Timestamps:

  • Introduction - 00:00
  • Clinal development optimization model - 2:37
  • Transferring between industries – 7:06
  • To what extent will AI impact research? - 11:56
  • China and the importance of early data - 15:23
  • Looking ahead - 16:35  

More from Deal-Making

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Deals Shaping The Industry, June 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.